Q3 Report 2019 – invitation to conference call and audiocast
On Thursday November 14, at 04.00 p.m. CET IRRAS will host a conference call and an online presentation of its Q3 2019 interim report (which will have been published earlier on the 14th at 08.00 a.m. CET). The presentation will be held in English.
The dial-in numbers for the conference call are:
Sweden: +46 8 50 55 83 54
Rest of the world: +44 33 33 00 92 74
The presentation will be webcast and can be accessed from the following web address: https://financialhearings.com/event/11742
Speakers: President CEO Kleanthis G. Xanthopoulos, Ph.D., CCO Will Martin and CFO Sabina Berlin
IRRAS AB is a global healthcare company focused on delivering innovative medical technologies to our customers and their patients. IRRAS designs, develops and commercializes products that improve patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methods in neurocritical care. IRRAS currently markets and sells its IRRAflow and Hummingbird product lines to hospitals worldwide through its direct sales organizations in the U.S. and select European countries and a network of distribution partners in other markets.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq First North Premier Growth Market (ticker: IRRAS). Redeye AB is Certified Adviser of the company with email email@example.com or phone +46 8 121 576 90.
For more information, please contact:
Kleanthis G. Xanthopoulos, Ph.D.
President and CEO
+46 73 951 9502
The information was released for public disclosure, through the agency of the contact person above, on October 31, 2019 at 8:00 a.m. (CET).